Genmab presents promising new data for cancer hope in US
The annual meeting of hematology association ASH is being held now, and the Danish biotech company has used the opportunity to present data for epcoritamab. One study reported an overall response rate of 85%.
by marketwire, translated by daniel pedersen
Biotech company Genmab is presenting several data sets from drug candidate epcoritamab for different types of lymphomas at the annual meeting of the American Society of Hematology (ASH), currently underway in New Orleans, Louisiana.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab has two potential blockbusters up its sleeve
For subscribers
Genmab expects important comparison study data next year
For subscribers
